SOURCE: Smallcap-Investors

February 02, 2010 09:07 ET

Biotech Stocks to Watch: TPIV, INO, MYGN, CRXL

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by

BOCA RATON, FL--(Marketwire - February 2, 2010) - TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed an R&D collaboration agreement with Aeras Global TB Vaccine Foundation.

Aeras Global is one the leading non-profit Product Development Partnerships dedicated to the development of an effective TB vaccine. Funders of Aeras include the Bill and Melinda Gates Foundation among others.

"Aeras is exploring novel approaches to enhance the effectiveness of new TB vaccines," said Jerald C. Sadoff, MD, the President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation. "We are looking forward to evaluating TapImmune's adjuvant technology in our next generation genetic vaccines."

Inovio Biomedical Corporation (AMEX: INO), engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines rose almost 5% yesterday.

Crucell N.V. (NASDAQ: CRXL), announced the release of Q4 and Full Year 2009 numbers on Tuesday, February 9th.

Myriad Genetics, Inc. (NASDAQ: MYGN) Will hold Second Quarter Fiscal 2010 Financial Results Conference call after market close.

About is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. Smallcap-Investors goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. offers a free financial newsletter. To subscribe or get more information, visit our home page located at . An affiliate of has been promised compensation by TapImmune Inc. for the dissemination of this Press Release

Contact Information